Literature DB >> 11100057

Parotid gland malignant melanomas.

R A Prayson1, B A Sebek.   

Abstract

BACKGROUND: Malignant melanomas are relatively unusual tumors in the parotid gland. The majority of previously reported cases appear to represent metastatic lesions, often from cutaneous head and neck primaries.
METHODS: Retrospective clinicopathologic review of 12 cases of malignant melanoma involving the parotid gland encountered between 1980 and October 1999 at a tertiary referral center.
RESULTS: Patients consisted of 9 men and 3 women ranging in age from 30 to 84 years (median, 66 years). Eleven of 12 patients presented with a neck mass or nodule. In 9 of 12 patients, a cutaneous or conjunctival primary was noted in the head region. In 2 patients, a cutaneous melanoma and the parotid gland melanoma were diagnosed at the same time. In 1 patient, melanoma was initially diagnosed in the parotid gland, and a definite primary was not uncovered. All patients underwent excision of the parotid melanoma, which was accompanied by a lymph node biopsy or dissection in 10 out of 11 patients. Four patients received adjuvant radiotherapy, and 3 patients received adjuvant chemotherapy. Four of 11 patients had ipsilateral cervical lymph node metastasis at the time of parotid tumor resection, and 5 patients had involvement of intraparotid lymph nodes by metastatic melanoma. Tumors ranged in size from 0.3 to 2.5 cm in greatest dimension. Multiple parotid nodules were noted in 4 patients. All tumors were characterized by a diffuse proliferation of cells with abundant eosinophilic cytoplasm and prominent nucleoli. Four tumors demonstrated focal spindle cell regions. Intravascular and/or lymphatic involvement by tumor within the parotid gland was noted in 3 lesions. At last known follow-up, 6 patients had died with tumor at a median follow-up period of 11 months after parotid gland surgery. Four patients were alive with evidence of tumor at follow-up intervals of 4, 17, 21, and 113 months after parotid gland surgery. Two patients were alive with no evidence of residual tumor at 20 and 148 months of follow-up.
CONCLUSIONS: The majority of melanomas involving the parotid gland appeared to be associated with lymph node metastasis in and around the gland from a cutaneous primary in the head region. Prognosis is generally poor, although rare patients may survive a long period of time following surgery.

Entities:  

Mesh:

Year:  2000        PMID: 11100057     DOI: 10.5858/2000-124-1780-PGMM

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  6 in total

Review 1.  Malignant melanoma of the conjunctiva metastasising to the parotid gland.

Authors:  F Cuthbertson; J Luck; S Rose
Journal:  Br J Ophthalmol       Date:  2003-11       Impact factor: 4.638

2.  Malignant melanoma of parotid gland in a child-our unique experience.

Authors:  Denish Apparau; Hema Apparau; Irfan Mohamad; Venkata Murali Krishna Bhavaraju
Journal:  AME Case Rep       Date:  2018-02-02

3.  Parotid melanoma of unknown primary.

Authors:  Jeffrey F Scott; Cheryl L Thompson; Ritva Vyas; Kord Honda; Chad Zender; Rod Rezaee; Pierre Lavertu; Henry Koon; Kevin D Cooper; Meg R Gerstenblith
Journal:  J Cancer Res Clin Oncol       Date:  2016-04-13       Impact factor: 4.553

Review 4.  Primary melanoma of submandibular gland: case report and literature review of a very rare entity.

Authors:  Hassan Mir Mohammad Sadeghi; Ramtin Dastgir; Shaghayegh Bozorg Zadeh; Fatemeh Mashhadiabbas; Abbas Karimi; Meysam Mohammadi Khah
Journal:  BMC Oral Health       Date:  2022-08-14       Impact factor: 3.747

5.  Direct bony invasion of malignant melanoma.

Authors:  Viswanath Mula; Adhip Mandal; Edward Britton; Vaidyanathan Shiv Shanker
Journal:  Indian J Orthop       Date:  2009-10       Impact factor: 1.251

6.  A rare case of metastatic malignant melanoma to the colon from an unknown primary.

Authors:  Preethi Reddy; Courtney Walker; Bianca Afonso
Journal:  Case Rep Gastrointest Med       Date:  2014-06-30
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.